Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
BEIJING, March 29, 2023 (GLOBE NEWSWIRE) -- Kingsoft Cloud Holdings Limited (“Kingsoft Cloud” or the “Company”) (NASDAQ: KC and HKEX: 3896), a leading independent cloud service provider in China,...
-
-- The two parties will collaborate to develop and commercialize toripalimab in 9 Southeast Asian countries through a joint venture company, Excellmab -- Excellmab will be responsible for the...
-
--三叶草生物在中国拥有两款优质的已获批的呼吸道领域疫苗（新冠疫苗和季节性流感疫苗），预计将在2023年带来有意义和多元的收入，保持连续的增长势头-- --三叶草生物的新冠疫苗现已在中国24个省市列入采购目录（人口覆盖率>80%），并处于市场有利地位，将成为即将到来的加强针接种普及的主要参与者; 预计2023年上半年在至少另外一个国家获得紧急使用授权（EUA），并签署双边供应协议-- ...
-
-- Clover’s two premium respiratory vaccines approved in China (COVID-19 and seasonal influenza) are expected to drive meaningful and diversified revenues in 2023 with continued growth thereafter -- ...
-
Shenzhen, China, March 28, 2023 (GLOBE NEWSWIRE) -- On March 28, 2023, Linklogis Inc. (09959.HK, “Linklogis”) released its 2022 annual results. The total revenue and income from principal ...
-
A total of 8,543 hotels or 809,478 hotel rooms in operation as of December 31, 2022.Hotel turnover1 increased 10.5% year-over-year to RMB13.1 billion in the fourth quarter of 2022, and increased 9.3%...
-
SHANGHAI, China, March 22, 2023 (GLOBE NEWSWIRE) -- Baozun Inc. (Nasdaq: BZUN and HKEX: 9991) (“Baozun”, the “Company” or the “Group”), a leading brand e-commerce solution provider and digital...
-
BEIJING, March 20, 2023 (GLOBE NEWSWIRE) -- KANZHUN LIMITED (“BOSS Zhipin” or the “Company”) (Nasdaq: BZ; HKEX: 2076), a leading online recruitment platform in China, today announced its unaudited...
-
BEIJING, March 20, 2023 (GLOBE NEWSWIRE) -- KANZHUN LIMITED (“BOSS Zhipin” or the “Company”) (Nasdaq: BZ; HKEX: 2076), a leading online recruitment platform in China, today announced that its board...
-
Third positive registrational trial met its primary endpoint, with KarXT demonstrating an 8.4-point reduction in PANSS total score compared to placebo at Week 5 (p<0.0001) KarXT was generally well...